Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Osteosarcoma 3Neuroblastoma 3Breast Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive 1Nerve Sheath Neoplasms 1Neoplasm Metastasis 1Myoepithelioma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Hodgkin Disease 1Giant Cell Tumor of Bone 1Desmoplastic Small Round Cell Tumor 1Clear-cell metastatic renal cell carcinoma 1Chordoma 1Chondrosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × Zoledronic Acid × 1 year × Clear all
NCT06374459 2026-04-20

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Washington University School of Medicine

Phase 1/2 Recruiting
152 enrolled
Breast

Breast Neoplasms

NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

NCT03664687 2026-02-09

REaCT-ZOL

Ottawa Hospital Research Institute

Phase 4 Completed
211 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡